Lakewood-Amedex Biotherapeutics, Inc. (LABT)
NASDAQ: LABT · Real-Time Price · USD
0.1960
-0.0413 (-17.40%)
Oct 30, 2026, 2:28 PM EDT - Market open

LABT Financials Overview

Millions USD. Fiscal year is Jan - Dec.

Revenue & Profits

Fiscal Year
TTMFY 2025FY 2024FY 2023
Period EndingJun '26 Dec '25 Dec '24 Dec '23
Operating Income
-7.27-3.77-4.03-8.64
Net Income
-8.97-5.85-6.86-8.28
Earnings Per Share
-10.20-8.40-9.92-12.16
EPS Growth
----

Cash & Debt

Fiscal Year
CurrentFY 2025FY 2024FY 2023
Period EndingJun '26 Dec '25 Dec '24 Dec '23
Cash & Investments
4.580.240.686.39
Total Debt
0.11.660.270.58
Net Cash (Debt)
4.48-1.420.415.81
Net Cash Growth
---92.97%-
Net Cash Per Share
5.10-2.050.598.53

Cash Flow & CapEx

Fiscal Year
TTMFY 2025FY 2024FY 2023
Period EndingJun '26 Dec '25 Dec '24 Dec '23
Operating Cash Flow
-3.49-1.94-5.72-6.82
Capital Expenditures
---0-
Free Cash Flow
-3.49-1.94-5.73-6.82
Free Cash Flow Growth
----